Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 8, 2015, Pages E881-E890

  Han, Byung Hee ^a   Zhou, Meng Liang ^a,b   Johnson, Andrew W ^a   Singh, Itender ^a   Liao, Fan ^a   Vellimana, Ananth K ^a   Nelson, James W ^a   Milner, Eric ^a   Cirrito, John R ^a   Basak, Jaco ^a   Yoo, Min ^a   Dietrich, Hans H ^a   Holtzman, David M ^a   Zipfel, Gregory Joseph ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Alzheimer' s disease; Cerebral amyloid angiopathy; NADPH oxidase; Reactive oxygen species; Vasomotor dysfunction

Indexed keywords

3 NITROTYROSINE; APOCYNIN; APOLIPOPROTEIN E; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SCAVENGER; TEMPOL; ACETOPHENONE DERIVATIVE; AMINE OXIDE; SPIN LABELING;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VESSEL REACTIVITY; BRAIN ARTERY; BRAIN HEMORRHAGE; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOREACTIVITY; LIPOPHILICITY; MEAN ARTERIAL PRESSURE; MICROHEMORRHAGE; MOUSE; MULTIPHOTON MICROSCOPY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SENILE PLAQUE; UPREGULATION; VASCULAR AMYLOIDOSIS; VASOMOTOR DISORDER; WESTERN BLOTTING; ADRENERGIC SYSTEM; AGING; ANIMAL; ASTROCYTE; BRAIN; C57BL MOUSE; COMPLICATION; DRUG EFFECTS; HAMSTER; HUMAN; METABOLISM; MICROGLIA; PATHOLOGY; PATHOPHYSIOLOGY; SMOOTH MUSCLE FIBER; SPIN LABELING; TRANSGENIC MOUSE; VASCULAR SMOOTH MUSCLE;

MUS;

ACETOPHENONES; AGING; ANIMALS; APOLIPOPROTEINS E; ASTROCYTES; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL ARTERIES; CEREBRAL HEMORRHAGE; CRICETINAE; CYCLIC N-OXIDES; HUMANS; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SPIN LABELS; VASOMOTOR SYSTEM;

EID: 84923686921     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1414930112     Document Type: Article

References (72)

1. Revesz T, et al. (2002) Sporadic and familial cerebral amyloid angiopathies. Brain Pathol 12(3):343-357.
2. Mann DM, et al. (1996) Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am J Pathol 148(4):1257-1266.
3. Sisodia SS (1999) Alzheimer's disease: Perspectives for the new millennium. J Clin Invest 104(9):1169-1170.
4. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81(2): 741-766.
5. Maia LF, Mackenzie IR, Feldman HH (2007) Clinical phenotypes of cerebral amyloid angiopathy. J Neurol Sci 257(1-2):23-30.
6. Nicoll JA, Yamada M, Frackowiak J, Mazur-Kolecka B, Weller RO (2004) Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease: Pro-CAA position statement. Neurobiol Aging 25(5):589-597; discussion 603- 604.
7. Vinters HV (1987) Cerebral amyloid angiopathy: A critical review. Stroke 18(2): 311-324.
8. Greenberg SM (2002) Cerebral amyloid angiopathy and vessel dysfunction. Cerebrovasc Dis 13(Suppl 2):42-47.
9. Okazaki H, Reagan TJ, Campbell RJ (1979) Clinicopathologic studies of primary cerebral amyloid angiopathy. Mayo Clin Proc 54(1):22-31.
10. Greenberg SM, Vonsattel JP, Stakes JW, Gruber M, Finklestein SP (1993) The clinical spectrum of cerebral amyloid angiopathy: Presentations without lobar hemorrhage. Neurology 43(10):2073-2079.
11. Vermeer SE, et al. (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348(13):1215-1222.
12. Itoh Y, Yamada M (1997) Cerebral amyloid angiopathy in the elderly: The clinicopathological features, pathogenesis, and risk factors. J Med Dent Sci 44(1):11-19.
13. Han BH, et al. (2008) Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: Contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. J Neurosci 28(50):13542-13550.
14. Suo Z, Fang C, Crawford F, Mullan M (1997) Superoxide free radical and intracellular calcium mediate A beta(1-42) induced endothelial toxicity. Brain Res 762(1-2): 144-152.
15. Niwa K, et al. (2001) A beta-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol 281(6):H2417-H2424.
16. Price JM, Sutton ET, Hellermann A, Thomas T (1997) beta-Amyloid induces cerebrovascular endothelial dysfunction in the rat brain. Neurol Res 19(5):534-538.
17. Paris D, et al. (2000) Soluble beta-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. Neurobiol Aging 21(2):183-197.
18. Paris D, et al. (1999) Inhibition of Alzheimer's beta-amyloid induced vasoactivity and proinflammatory response in microglia by a cGMP-dependent mechanism. Exp Neurol 157(1):211-221.
19. Tong XK, Nicolakakis N, Kocharyan A, Hamel E (2005) Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. J Neurosci 25(48):11165-11174.
20. Nicolakakis N, et al. (2008) Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci 28(37):9287-9296.
21. Borchelt DR, et al. (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19(4): 939-945.
22. Price JM, Chi X, Hellermann G, Sutton ET (2001) Physiological levels of beta-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production. Neurol Res 23(5):506-512.
23. Niwa K, Carlson GA, Iadecola C (2000) Exogenous A beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab 20(12):1659-1668.
24. Iadecola C, et al. (1999) SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci 2(2):157-161.
25. Niwa K, et al. (2000) Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci USA 97(17):9735-9740.
26. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C (2002) Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis 9(1):61-68.
27. Christie R, Yamada M, Moskowitz M, Hyman B (2001) Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am J Pathol 158(3):1065-1071.
28. Park L, et al. (2008) Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc Natl Acad Sci USA 105(4):1347-1352.
29. Park L, et al. (2004) Abeta-induced vascular oxidative stress and attenuation of functional hyperemia in mouse somatosensory cortex. J Cereb Blood Flow Metab 24(3):334-342.
30. Park L, et al. (2005) NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. J Neurosci 25(7): 1769-1777.
31. Block ML (2008) NADPH oxidase as a therapeutic target in Alzheimer's disease. BMC Neurosci 9(Suppl 2):S8.
32. Brandes RP, Schröder K (2008) Differential vascular functions of Nox family NADPH oxidases. Curr Opin Lipidol 19(5):513-518.
33. Rivera J, Sobey CG, Walduck AK, Drummond GR (2010) Nox isoforms in vascular pathophysiology: Insights from transgenic and knockout mouse models. Redox Rep 15(2):50-63.
34. Iadecola C (2003) Cerebrovascular effects of amyloid-beta peptides: Mechanisms and implications for Alzheimer's dementia. Cell Mol Neurobiol 23(4-5):681-689.
35. Park L, Anrather J, Girouard H, Zhou P, Iadecola C (2007) Nox2-derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. J Cereb Blood Flow Metab 27(12):1908-1918.
36. Garcia-Alloza M, et al. (2009) Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice. J Neurochem 109(6):1636-1647.
37. Esposito L, et al. (2006) Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J Neurosci 26(19):5167-5179.
38. Rodrigo J, et al. (2004) Nitric oxide in the cerebral cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice. Neuroscience 128(1):73-89.
39. Trumbull KA, et al. (2012) Diapocynin and apocynin administration fails to significantly extend survival in G93A SOD1 ALS mice. Neurobiol Dis 45(1):137-144.
40. Brendza RP, et al. (2005) Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest 115(2):428-433.
41. Han BH, et al. (2011) Resorufin analogs preferentially bind cerebrovascular amyloid: Potential use as imaging ligands for cerebral amyloid angiopathy. Mol Neurodegener 6(1):86.
42. Hsiao K, et al. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274(5284):99-102.
43. Kawarabayashi T, et al. (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21(2):372-381.
44. Koenigsknecht-Talboo J, et al. (2008) Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci 28(52):14156-14164.
45. Fryer JD, et al. (2003) Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J Neurosci 23(21):7889-7896.
46. Fryer JD, et al. (2005) Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci 25(11):2803-2810.
47. Shin HK, et al. (2007) Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain 130(Pt 9):2310-2319.
48. Dietrich HH, Xiang C, Han BH, Zipfel GJ, Holtzman DM (2010) Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells. Mol Neurodegener 5:15.
49. Dorr A, et al. (2012) Amyloid-β-dependent compromise of microvascular structure and function in a model of Alzheimer's disease. Brain 135(Pt 10):3039-3050.
50. Christie R, Kimchi E, Kajdasz S, Bacskai B, Hyman BT (2001) Multiphoton microscopy and amyloid angiopathy. Amyloid 8(Suppl 1):48-50.
51. Mandybur TI (1986) Cerebral amyloid angiopathy: The vascular pathology and complications. J Neuropathol Exp Neurol 45(1):79-90.
52. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M (1996) Beta-amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380(6570):168-171.
53. Thomas T, McLendon C, Sutton ET, Thomas G (1997) Cerebrovascular endothelial dysfunction mediated by beta-amyloid. Neuroreport 8(6):1387-1391.
54. Zipfel GJ, Han BH, Ford AL, Lee J-M (2009) Cerebral amyloid angiopathy: Progressive disruption of the neurovascular unit. Stroke 40(Suppl 3):S16-S19.
55. Gentile MT, et al. (2004) Mechanisms of soluble beta-amyloid impairment of endothelial function. J Biol Chem 279(46):48135-48142.
56. Stefanska J, Pawliczak R (2008) Apocynin: Molecular aptitudes. Mediators Inflamm 2008:106507.
57. Heumüller S, et al. (2008) Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 51(2):211-217.
58. Bieschke J, Zhang Q, Powers ET, Lerner RA, Kelly JW (2005) Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. Biochemistry 44(13):4977-4983.
59. Liu L, Komatsu H, Murray IV, Axelsen PH (2008) Promotion of amyloid beta protein misfolding and fibrillogenesis by a lipid oxidation product. J Mol Biol 377(4): 1236-1250.
60. Sung S, et al. (2004) Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol 165(6):2197-2206.
61. Yang F, et al. (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280(7):5892-5901.
62. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ (2007) Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102(4):1095-1104.
63. Hartman RE, et al. (2006) Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease. Neurobiol Dis 24(3):506-515.
64. Quinn J, et al. (2005) Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: Implications for clinical trials. Brain Res 1037(1-2):209-213.
65. Li F, et al. (2004) Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J Neurochem 89(5):1308-1312.
66. Massaad CA, Washington TM, Pautler RG, Klann E (2009) Overexpression of SOD-2 reduces hippocampal superoxide and prevents memory deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 106(32):13576-13581.
67. Zhang Y, et al. (2005) Apocynin but not allopurinol prevents and reverses adrenocorticotropic hormone-induced hypertension in the rat. Am J Hypertens 18(7):910-916.
68. Tang XN, Cairns B, Cairns N, Yenari MA (2008) Apocynin improves outcome in experimental stroke with a narrow dose range. Neuroscience 154(2):556-562.
69. Selemidis S, Sobey CG, Wingler K, Schmidt HH, Drummond GR (2008) NADPH oxidases in the vasculature: Molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther 120(3):254-291.
70. Holtzman DM, et al. (2000) Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 47(6):739-747.
71. Radde R, et al. (2006) Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7(9):940-946.
72. Liu F, et al. (2009) Apocynin attenuates tubular apoptosis and tubulointerstitial fibrosis in transgenic mice independent of hypertension. Kidney Int 75(2):156-166.